The Carlyle Group has acquired a significant minority stake in Ambio Holdings, a U.S. based pharmaceutical company focused on peptides, a cell component important for biological functions, according to an announcement.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
